[Bacteria isolated from intraabdominal infection and their susceptibilities to antimicrobial agents]. 1994

N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
First Department of Surgery, Nagoya City University Medical School.

Bacteria isolated from intraabdominal infections during the period from July 1982 to June 1993 were investigated with regard to their classifications according to a joint research by 9 university hospitals in Japan. The following results were obtained. 1. A total of 971 strains were isolated from 684 out of 597 patients with peritonitis, and 287 strains out of 971 were isolated from postoperative peritonitis. 2. The most predominant organism isolated from patients with acute peritonitis was Escherichia coli (28%), followed by Bacteroides fragilis group (17%), Gram-positive anaerobic cocci (16%), Enterococcus spp. (9%) and Klebsiella spp. (8%). 3. Against E. coli, cefmenoxime, cefuzonam, cefozopran, aztreonam and carumonam showed MIC50 less than 0.05 micrograms/ml. Against B. fragilis group, erthromycin, clindamycin, imipenem, lincomycin and latamoxef showed MIC50 less than 0.78 micrograms/ml. 4. The most predominant organism isolated from patients with postoperative peritonitis was Enterococcus spp. (20%) and followed by Pseudomonas spp. (14%), and Staphylococcus spp. (13%), E. coli (9%), Enterobacter spp. (8%) and Klebsiella spp. (8%). We suggest that cefazolin, cefmetazole, flomoxef, cefmenoxime, cefuzonam, and latamoxef are the first choice agents in empiric therapy for the treatment of acute peritonitis.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
August 2007, The Japanese journal of antibiotics,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
January 2005, Hepato-gastroenterology,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
January 1992, Antimicrobial agents and chemotherapy,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
June 2015, The Japanese journal of antibiotics,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
November 1985, Journal of periodontology,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
November 1985, Journal of periodontology,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
January 1996, Antimicrobial agents and chemotherapy,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
July 1994, Antimicrobial agents and chemotherapy,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
February 2012, Antimicrobial agents and chemotherapy,
N Shinagawa, and A Mizuno, and K Mashita, and J Yura, and S Ishikawa, and K Hirata, and R Denno, and M Mukaiya, and K Ishibiki, and N Aikawa
January 2002, The Journal of international medical research,
Copied contents to your clipboard!